ArticleThe journal of nutrition, health & aging2009
What are the outcomes of treatment among patients with sarcopenia?
Article in The journal of nutrition, health & aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Trial
- Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force.The Journal of frailty & aging · 2020Article
- RISK FACTORS FOR SLOW GAIT SPEED: A NESTED CASE-CONTROL SECONDARY ANALYSIS OF THE MEXICAN HEALTH AND AGING STUDY.The Journal of frailty & aging · 2015Article
- Frailty and sarcopenia: definitions and outcome parameters.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Review
- Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research).The journal of nutrition, health & aging · 2011Article
- Clinical trials on sarcopenia: methodological issues regarding phase 3 trials.Clinics in geriatric medicine · 2011Review
- Sarcopenia with limited mobility: an international consensus.Journal of the American Medical Directors Association · 2011Article
- Carla Task Force on Sarcopenia: propositions for clinical trials.The journal of nutrition, health & aging · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Treatment outcomes for clinical trials of interventions on sarcopenia depend on the goals of the intervention, especially whether the treatment is considered therapeutic or preventive. Key issues regarding outcomes are the selection of a primary outcome and options for secondary outcomes. While clinical significance and face validity are key concerns when making this determination, other factors to be incorporated into the decision include measurement characteristics, feasibility and cost, risks of missing outcomes and options for alternative strategies to determine them. Primary should be highly responsive to changes in sarcopenia and clinically important. Like many problems of aging, functional abilities, especially mobility, may be the most clinically relevant states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.